(Q34038573)

30 July 2017

1 reference

title

Recent approaches in acute lymphoblastic leukemia in adults. (English)

1 reference

30 July 2017

1 reference

lymphoblastic leukemia

1 reference

Hoelzer D

1

1 reference

30 July 2017

Gökbuget N

series ordinal

2

1 reference

30 July 2017

publication date

1 October 2000

1 reference

Critical Reviews in Oncology Hematology

30 July 2017

published in

1 reference

30 July 2017

volume

36

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

49-58

1 reference

Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

Improved results of an intensified therapy in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

Results of Medical Research Council trial UKALL IX in acute lymphoblastic leukaemia in adults: report from the Medical Research Council Working Party on Adult Leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

The GIMEMA ALL 0183 trial: analysis of 10-year follow-up. GIMEMA Cooperative Group, Italy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

Intensification of treatment for adults with acute lymphoblastic leukaemia: results of U.K. Medical Research Council randomized trial UKALL XA. Medical Research Council Working Party on Leukaemia in Adults

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

Improved outcome of adult acute lymphoblastic leukaemia by moderately intensified chemotherapy which includes a 'pre-induction' course for rapid tumour reduction: preliminary results on 66 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

Intensive induction/consolidation therapy without maintenance in adult acute lymphoblastic leukaemia: a pilot assessment. Working Party on Leukaemia of the Swiss Group for Epidemiologic and Clinical Cancer Research (SAKK)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

Meningeosis leukaemica in adult acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

The clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification by antigen-receptor gene sequences

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

Detection of residual disease in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900097-4

7 January 2021

10.1016/S1040-8428(00)00097-4

Identifiers

DOI

1 reference

30 July 2017

1 reference